Surveillance Bronchoscopy for the Care of Lung Transplant Recipients: A Retrospective Single Center Analysis
Lung transplantation is often the only treatment for end-stage lung disease. Following lung transplantation, infections and transplant rejections are major obstacles to short- and long-term success. Therefore, close monitoring for these complications is required after lung transplantation. The role...
Gespeichert in:
Veröffentlicht in: | Transplantation proceedings 2021-01, Vol.53 (1), p.265-272 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Lung transplantation is often the only treatment for end-stage lung disease. Following lung transplantation, infections and transplant rejections are major obstacles to short- and long-term success. Therefore, close monitoring for these complications is required after lung transplantation. The role of prescheduled surveillance bronchoscopies after lung transplantation is controversial. Thus, we aimed to retrospectively analyze the therapeutic implications of surveillance bronchoscopies in 110 consecutive lung transplant recipients.
Results of 400 prescheduled surveillance bronchoscopies of 110 consecutive lung transplant recipients were analyzed. Positive results (pathologic histology, microbiology, or virology) were further investigated for their effect on clinical decision making. Additionally, cellular composition of bronchoalveolar lavage (BAL) was analyzed.
Two hundred five surveillance bronchoscopies showed pathologic findings. In 81 cases clinical treatment was changed based on the results. That is, 20% of all prescheduled bronchoscopies directly influenced clinical decision making. Furthermore, analyses of BAL indicate that increased alveolar eosinophils are associated with an increased risk of transplant rejection.
Prescheduled surveillance bronchoscopies identify clinically unsuspected but therapeutically relevant pathologic findings in approximately 20% of cases. BAL cell composition may confer additional information, especially in cases when biopsy is not possible.
•Prescheduled surveillance bronchoscopies after lung transplantation may influence therapeutic decision making in up to 20% of cases.•Unexpected microbiological findings and unexpected acute cellular rejection are the most important findings for changing therapy.•Bronchoalveolar lavage and alveolar differential cell count may help to identify patients at risk for acute rejection; for example, in cases when parenchymal biopsies are not possible. |
---|---|
ISSN: | 0041-1345 1873-2623 |
DOI: | 10.1016/j.transproceed.2020.08.011 |